Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Safety and preliminary efficacy of anti-CD19 CAR T cells zorpocabtagene-autoleucel in systemic autoimmune diseases: Final analysis of the castle trial

Blood (2025) 146 (Supplement 1): 2380.

https://doi.org/10.1182/blood-2025-2380

Published: 2025

Journal Articles

Pre-existing clonal hematopoiesis in CAR-T recipients is not associated with increased immunotoxicity and inflammatory serum signatures

Giulia Rappa, Frank Ziemann, Kieron White, Amelie Muth, Cristina Zucchinetti, Maja Rothenberg-Thurley, Tobias Tix, Agnese Petrera, Bianka Ksienzyk, Charlotte Bentenrieder, Fabian Müller, Veit Buecklein, Kai Rejeski, Marion Subklewe

Blood (2025) 146 (Supplement 1): 2366.

https://doi.org/10.1182/blood-2025-2366

Published: 2025

Journal Articles

Real-world use of loncastuximab tesirine in heavily pretreated and high risk relapsed/refractory large B-cell lymphoma patients: German multicenter analysis

Evgenii Shumilov, Débora-Michèle Grote Urtubey, Marcel Teichert, Maximilian Seib, Rebecca Wurm-Kuczera, Joseph Kauer, Friedrich-Linus Roessiger, Tobias Tix, Alexander Hölscher, Philipp Gödel, Christoph Brey, Paolo Mazzeo, Zoi Saxonis, Belana Kuhn, Vanja Zeremski, Franziska Brunner, Susanne Ghandili, Enver Aydilek, Markus Maulhardt, Philipp Nakov, Gregor Friedrich, Christian Schultze-Florey, Giuliano Filippini Velazquez, Igor Age Kos, Anna Ossami Saidy, Christoph Kimmich, Maika Klaiber-Hakimi, Philipp Berning, Andrea Kerkhoff, Bertram Glass, Isabelle Krämer, Lorenz Thurner, Mathias Lutz, Florian Heidel, Vladan Vucinic, Christiane Pott, Andreas Viardot, Gerald Wulf, Thomas Weber, Dimitrios Mougiakakos, Francis Ayuk, Udo Holtick, Sascha Dietrich, Niklas Gebauer, Ulf Schnetzke, Mathias Hänel, Martin Dreyling, Peter Dreger, Björn Chapuy, Fabian Müller, Bastian von Tresckow, Georg Lenz

Blood (2025) 146 (Supplement 1): 5473.

https://doi.org/10.1182/blood-2025-5473

Published: 2025

Journal Articles

CAR T-cells or bispecific antibodies for relapsed/refractory multiple myeloma: Head-to-head real-world european comparison

Blood (2025) 146 (Supplement 1): 4590.

https://doi.org/10.1182/blood-2025-4590

Published: 2025

Journal Articles

Late re-expansion and high-level persistence of CAR T-cells can be driven by single CAR+ T-cell clones without clinically evident CAR+ T-cell lymphoma

Fabian Müller, Nora Rebecca Schwingen, Anne Hartebrodt, Nicolai Meyerhoefer, Guranda Chitadze, Soraya Kharboutli, Heiko Bruns, Arif Ekici, Kerstin Schäfer-Eckart, Stefan Knop, Frederik Graw, David Blumenthal, Michael Rehli, Monika Brüggemann, Andreas Mackensen, Simon Voelkl

Blood (2025) 146 (Supplement 1): 4171.

https://doi.org/10.1182/blood-2025-4171

Published: 2025

Journal Articles

Prognostic role of FDG-PET in outcomes of relapsed/refractory large B-cell lymphoma treated with CD3-CD20 directed bispecific antibodies

Sophie Wollnitza, David Ventura, Marcel Teichert, Fabian Freisleben, Hristo Boyadzhiev, Robert Seifert, Michelle Amon, Julia Scholz, Alexander Pohlmann, Akhil Behringer, Philipp Backhaus, Philipp Schindler, Wolfgang Roll, Fabian Müller, Thomas Pabst, Michael Schaefers, Bastian von Tresckow, Evgenii Shumilov, Georg Lenz

Blood (2025) 146 (Supplement 1): 5518.

https://doi.org/10.1182/blood-2025-5518

Published: 2025

Journal Articles

Phase II frontline chemolight R-pola-glo trial induces high and durable response rates in elderly and medically unfit/frail patients with aggressive B-cell lymphoma

Blood (2025) 146 (Supplement 1): 61.

https://doi.org/10.1182/blood-2025-61

Published: 2025

Journal Articles

Impact of bridging therapy on efficacy of CD19 CAR T cell therapy in diffuse-large B cell lymphoma: Histology and the choice of drug matter

Blood (2025) 146 (Supplement 1): 1949.

https://doi.org/10.1182/blood-2025-1949

Published: 2025

Journal Articles

Distinct inflammatory and immune recovery patterns after CD19-directed CAR T-cell therapy in SLE and B-cell lymphoma

Nora Rebecca Schwingen, Fabian Müller, Melanie Hagen, Andreas Wirsching, Michael Aigner, Sascha Kretschmann, Soraya Kharboutli, Julia Scholz, Giulia Benintende, Jule Taubmann, Tobias Krickau, Nora Naumann-Bartsch, Heiko Bruns, Ricardo Grieshaber-Bouyer, Frederik Graw, Markus Metzler, Georg Schett, Andreas Mackensen, Simon Voelkl

Blood (2025) 146 (Supplement 1): 1947.

https://doi.org/10.1182/blood-2025-1947

Published: 2025

Journal Articles

Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment

Blood (2025) 146 (11): 1300–1313.

https://doi.org/10.1182/blood.2024027877

Published: 2025

Includes: Supplemental data

Journal Articles

Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma

Blood (2025) 146 (9): 1088–1095.

https://doi.org/10.1182/blood.2025028375

Published: 2025

Includes: Supplemental data

Journal Articles

Alterations of Immune Cells By Large B Cell Lymphoma Persist Years after Achieving Complete Remission and Correlate with Impaired Adaptive Immunity

Richard Pelzl, Sabrina Kübel, Paulina Klein, Franziska Gsottberger, Kerstin Wendland, Srdjan Petkovic, Valeska Brueckl, Rebecca Baur, Simon Voelkl, Andreas Mackensen, Krystelle Nganou-Makamdop, Fabian Müller

Blood (2022) 140 (Supplement 1): 6432–6433.

https://doi.org/10.1182/blood-2022-167216

Published: 2022

Journal Articles

Myc -Driven, Primary Mouse Lymphoma Expressing Human CD22 Are Highly Infiltrated By Syngeneic Immune Cells and Provide a Unique Model to Test CD22-Targeted Therapies

Franziska Wagner, Carolin Brandl, Charlotte Emmerich, Andreas Mackensen, MD, Lars Nitschke, Fabian Müller, MD

Blood (2018) 132 (Supplement 1): 1673.

https://doi.org/10.1182/blood-2018-99-110284

Published: 2018

Journal Articles

Cellular Reprogramming Erases Aberrant DNA Methylation and the Malignant Phenotype in Chronic Myeloid Leukemia

Giovanni Amabile, PhD, Annalisa Di Ruscio, MDPhD, Fabian Muller, PhD, Robert S Welner, PhD, Henry Yang, PhD, Alexander K Ebralidze, PhD, Hong Zhang, PhD, Lihua Qi, PhD, Giovanni Martinelli, MD, Thijn Brummelkamp, PhD, Michelle M. Le Beau, PhD, Maria E Figueroa, MD, Christoph Bock, PhD, Daniel G Tenen, MD

Blood (2014) 124 (21): 4524.

https://doi.org/10.1182/blood.V124.21.4524.4524

Published: 2014

Journal Articles

B-Cell Receptors of Primary Central Nervous System Lymphoma Recognize Antigens in the Brain

Martin Trepel, Fabian Müller, Gerald Illerhaus, MD, Markus Glatzel, Mascha Binder, Elmar Spies

Blood (2014) 124 (21): 3003.

https://doi.org/10.1182/blood.V124.21.3003.3003

Published: 2014

Journal Articles

CLL B-cell receptors can recognize themselves: alternative epitopes and structural clues for autostimulatory mechanisms in CLL

Mascha Binder, Fabian Müller, Mareike Frick, Claudia Wehr, Frédéric Simon, Bernd Leistler, Hendrik Veelken, Roland Mertelsmann, Martin Trepel

Blood (2013) 121 (1): 239–241.

https://doi.org/10.1182/blood-2012-09-454439

Published: 2013

Journal Articles

Evidence for Autostimulatory Mechanisms in Chronic Lymphocytic Leukemia.

Martin Trepel, MD, PhD, Fabian Muller, MD, Mareike Frick, MD, Janina Rahlff, Claudia Wehr, Frederic Simon, PhD, Bernd Leistler, PhD, Hendrik Veelken, MD PhD, Roland H. Mertelsmann, MD, PhD, Mascha Binder, MD

Blood (2012) 120 (21): 2880.

https://doi.org/10.1182/blood.V120.21.2880.2880

Published: 2012

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Safety and preliminary efficacy of anti-CD19 CAR T cells zorpocabtagene-autoleucel in systemic autoimmune diseases: Final analysis of the castle trial

Pre-existing clonal hematopoiesis in CAR-T recipients is not associated with increased immunotoxicity and inflammatory serum signatures

Real-world use of loncastuximab tesirine in heavily pretreated and high risk relapsed/refractory large B-cell lymphoma patients: German multicenter analysis

CAR T-cells or bispecific antibodies for relapsed/refractory multiple myeloma: Head-to-head real-world european comparison

Late re-expansion and high-level persistence of CAR T-cells can be driven by single CAR+ T-cell clones without clinically evident CAR+ T-cell lymphoma

Prognostic role of FDG-PET in outcomes of relapsed/refractory large B-cell lymphoma treated with CD3-CD20 directed bispecific antibodies

Phase II frontline chemolight R-pola-glo trial induces high and durable response rates in elderly and medically unfit/frail patients with aggressive B-cell lymphoma

Impact of bridging therapy on efficacy of CD19 CAR T cell therapy in diffuse-large B cell lymphoma: Histology and the choice of drug matter

Distinct inflammatory and immune recovery patterns after CD19-directed CAR T-cell therapy in SLE and B-cell lymphoma

Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment

Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma

Alterations of Immune Cells By Large B Cell Lymphoma Persist Years after Achieving Complete Remission and Correlate with Impaired Adaptive Immunity

Myc -Driven, Primary Mouse Lymphoma Expressing Human CD22 Are Highly Infiltrated By Syngeneic Immune Cells and Provide a Unique Model to Test CD22-Targeted Therapies

Cellular Reprogramming Erases Aberrant DNA Methylation and the Malignant Phenotype in Chronic Myeloid Leukemia

B-Cell Receptors of Primary Central Nervous System Lymphoma Recognize Antigens in the Brain

CLL B-cell receptors can recognize themselves: alternative epitopes and structural clues for autostimulatory mechanisms in CLL

Evidence for Autostimulatory Mechanisms in Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only